{
  "first_published_at": "2012-02-10", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON143611", 
  "title": "Blue dyes: risk of serious allergic reactions", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\", \"radiology-imaging\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\", \"Radiology and imaging\"]}", 
  "_document_number": 122, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer", 
    "radiology-imaging"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Blue dyes: risk of serious allergic reactions</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Blue dyes (eg Patent Blue V, isosulfan blue) used for imaging purposes during surgery are associated with the occurrence of serious allergic reactions, including anaphylaxis. Surgeons are reminded to have competent personnel and emergency facilities available for at least 1 hour after administration of the blue dye.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Blue dyes such as Patent Blue V imported from the EU are used in lymphatic mapping for sentinel lymph node biopsy (SLNB) in breast surgery. Patent Blue V does not carry a UK marketing authorisation.</p>\n\n<p>On the basis of a clinical study (the ALMANAC trial)<cite>Mansel RE, et al. J Natl Cancer Inst 2006; 98: 599&#8211;609.</cite> and follow-up program (the NEW START program) serious allergic reactions were estimated at an incidence rate of 0.1%. Since 1975 a total of 70 case reports of allergic reactions with Patent Blue V were reported to us. 58 of these reports have been received since 2007, 26 of which were serious reactions. With currently increasing usage of Patent Blue V in the UK, the number of serious allergic reactions reported to us is also expected to rise.</p>\n\n<p>The UK Pharmacovigilance Expert Advisory Group of the Commission on Human Medicines advised that emergency measures should be available to treat patients that may experience allergic reactions or anaphylaxis.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Surgeons using blue dyes are reminded to remain aware of the risk of serious allergic reactions, including anaphylaxis</li>\n\n<li>Competent personnel and emergency facilities should be available for at least 1 hour after administration of blue dye because delayed reactions may occur</li>\n\n<li>Please report suspected adverse reactions via the Yellow Card scheme (<a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a>) even though blue dyes are unlicensed products, and include the seriousness of the reported reaction</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>See also a <a href=\"/Opendocuments/OpenPDFdocuments/CON143630\">letter for healthcare professionals</a>. This letter will also be circulated in partnership with the <a href=\"http://www.associationofbreastsurgery.org.uk/\" target=\"_blank\">Association of Breast Surgery</a></p>\n\n<p>Prescribers&#8217; responsibilities regarding <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990\" target=\"_blank\">off-label or unlicensed use of medicines</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update Feb 2012 vol 5, issue 7: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Blue dyes such as Patent Blue V imported from the EU are used in lymphatic mapping for sentinel lymph node biopsy (SLNB) in breast surgery. Patent Blue V does not carry a UK marketing authorisation.</p>\n\n<p>On the basis of a clinical study (the ALMANAC trial)<cite>Mansel RE, et al. J Natl Cancer Inst 2006; 98: 599&#8211;609.</cite> and follow-up program (the NEW START program) serious allergic reactions were estimated at an incidence rate of 0.1%. Since 1975 a total of 70 case reports of allergic reactions with Patent Blue V were reported to us. 58 of these reports have been received since 2007, 26 of which were serious reactions. With currently increasing usage of Patent Blue V in the UK, the number of serious allergic reactions reported to us is also expected to rise.</p>\n\n<p>The UK Pharmacovigilance Expert Advisory Group of the Commission on Human Medicines advised that emergency measures should be available to treat patients that may experience allergic reactions or anaphylaxis.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Surgeons using blue dyes are reminded to remain aware of the risk of serious allergic reactions, including anaphylaxis</li>\n\n<li>Competent personnel and emergency facilities should be available for at least 1 hour after administration of blue dye because delayed reactions may occur</li>\n\n<li>Please report suspected adverse reactions via the Yellow Card scheme (<a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a>) even though blue dyes are unlicensed products, and include the seriousness of the reported reaction</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p>See also a <a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con143630.pdf\" target='new\"\"'>letter for healthcare professionals<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (111Kb). This letter will also be circulated in partnership with the <a href=\"http://www.associationofbreastsurgery.org.uk/\" target=\"_blank\">Association of Breast Surgery</a></p>\n\n<p>Prescribers&#8217; responsibilities regarding <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990\" target=\"_blank\">off-label or unlicensed use of medicines</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update Feb 2012 vol 5, issue 7: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-02-01", 
  "date_last_modified": "2012-03-07", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "letter for healthcare professionals", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con143630.pdf", 
      "filename": "downloads/198dfe3c99853f4a1e56626085a1ba786b51a18b/con143630.pdf", 
      "original_filename": "con143630.pdf"
    }
  ], 
  "_item_id": 122, 
  "summary": "Blue dyes (eg Patent Blue V, isosulfan blue) used for imaging purposes during surgery are associated with the occurrence of serious allergic reactions, including anaphylaxis. Surgeons are reminded to have competent personnel and emergency facilities available for at least 1 hour after administration of the blue dye.", 
  "body": "Article date: February 2012\n\nBlue dyes such as Patent Blue V imported from the EU are used in lymphatic mapping for sentinel lymph node biopsy (SLNB) in breast surgery. Patent Blue V does not carry a UK marketing authorisation.\n\nOn the basis of a clinical study (the ALMANAC trial)[^1] and follow-up program (the NEW START program) serious allergic reactions were estimated at an incidence rate of 0.1%. Since 1975 a total of 70 case reports of allergic reactions with Patent Blue V were reported to us. 58 of these reports have been received since 2007, 26 of which were serious reactions. With currently increasing usage of Patent Blue V in the UK, the number of serious allergic reactions reported to us is also expected to rise. \n\nThe UK Pharmacovigilance Expert Advisory Group of the Commission on Human Medicines advised that emergency measures should be available to treat patients that may experience allergic reactions or anaphylaxis.\n\nAdvice for healthcare professionals:  \n  \n  * Surgeons using blue dyes are reminded to remain aware of the risk of serious allergic reactions, including anaphylaxis  \n  * Competent personnel and emergency facilities should be available for at least 1 hour after administration of blue dye because delayed reactions may occur  \n  * Please report suspected adverse reactions via the Yellow Card scheme ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)) even though blue dyes are unlicensed products, and include the seriousness of the reported reaction  \n  \nFurther information:\n\nSee also a [ASSET_TAG](#ASSET0) (111Kb). This letter will also be circulated in partnership with the [Association of Breast Surgery](http://www.associationofbreastsurgery.org.uk/)\n\nPrescribers’ responsibilities regarding [off-label or unlicensed use of medicines](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990)\n\n \n\nArticle citation: Drug Safety Update Feb 2012 vol 5, issue 7: A2.\n\n[^1]: Mansel RE, et al. J Natl Cancer Inst 2006; 98: 599–609.\n"
}